HOW WE HELP

0
Donated to NET cancer research
0
Annual visitors to online resources
0
Annual patient email & phone inquiries
0
Patient & caregiver education sessions
0
NET Reference Guides distributed across Canada
0
Patients & caregivers attend in person Support Groups annually
0
Online private patient & caregiver support group members
0
Assist patients in advocating for access to treatments & diagnostics

NET Cancer is the FASTEST growing class of CANCER worldwide

HELP US HELP OTHERS
HELP US HELP OTHERS

NEUROENDOCRINE TUMOURS (NETs) OVERVIEW

  • Neuroendocrine tumours (NETs) are abnormal growth of cells (neoplasms) that arise from cells of the diffuse neuroendocrine system.

  • NETs are considered complex tumours because both tumor growth and hormonal function must be addressed.

  • NETs are most common in the lung or gastrointestinal system, but they can also originate in other parts of the body such as the thyroid, thymus, pancreas, adrenals, paraganglia, ovaries and testes.

  • NETs are classified as functional (produce hormones that cause symptoms), or non-functional (may or may not produce hormones and do not cause hormonal symptoms).

  • The cause of NETs is currently unknown.

NET ONE PAGE FACTS

CNETS NEWS

From Gallstones to Cancer: A Mother’s Journey with NETs

September 11th, 2021|Comments Off on From Gallstones to Cancer: A Mother’s Journey with NETs

Our amazing Hamilton/Halton /Niagara NET Support Group Leader, Vannesa Mann, shares her inspirational story! Zoomer | September 10th, 2021 For people with neuroendocrine tumours, early diagnosis and timely access to approved treatments [...]

Pewter Zebra Keyfobs/Pendants

August 23rd, 2021|Comments Off on Pewter Zebra Keyfobs/Pendants

Volunteers create one-of-a-kind handmade Pewter Zebra Keyfobs/Pendants to help raise awareness & funds for CNETS Al Gillis is a neuroendocrine cancer patient and member of the Toronto Patient and Caregiver support group. One of [...]

Temozolomide Access in Ontario

July 6th, 2021|Comments Off on Temozolomide Access in Ontario

CNETS is pleased to share the news that the oral chemotherapy drug, temozolomide, often used in combination with capecitabine, known as the CAPTEM regimen, is now more accessible to Ontario-based neuroendocrine tumour (NET) patients.  [...]

Lutathera Funded in Saskatchewan

July 6th, 2021|Comments Off on Lutathera Funded in Saskatchewan

As of June 1, 2021, Lutathera is now available in Saskatchewan. The reimbursement criteria is for patients with unresectable, well-differentiated midgut* neuroendocrine tumors (NET) in patients who have experienced radiographic disease progression during somatostatin [...]

COVID-19 VACCINE & NEUROENDOCRINE CANCER PATIENTS

March 19th, 2021|Comments Off on COVID-19 VACCINE & NEUROENDOCRINE CANCER PATIENTS

Disclaimer: CNETS is a patient organization, and we are unable to provide medical advice. Any information or guidance contained herein should not replace personalized medical advice. Our objective is to provide you with general [...]

LUTATHERA Funded In British Columbia

March 8th, 2021|Comments Off on LUTATHERA Funded In British Columbia

CNETS is happy to announce that BC Cancer will now reimburse LUTATHERA for the approved indication. The BC Cancer Benefit Drug List, Published March 2021, Tumour Site: Gastrointestinal Peptide Receptor Radionuclide Therapy (PRRT) using [...]

CNETS PRIORITIES

SUPPORT

  • In-person peer-led support groups meetings
  • Dedicated patient email and phone support
  • Online private support groups for patients & caregivers

EDUCATION

  • Patient and caregiver education sessions across Canada
  • Robust online patient educational resources
  • Printed educational resources including the NET Reference Guide
  • Annual NET Medical and Scientific Meeting

AWARENESS

  • Raise awareness of NET cancer to the general public & the medical community
  • Participate in World NET Cancer Day Activities

ADVOCACY

  • Assist patients in advocating for access to treatments and diagnostics

RESEARCH

  • Fund Canadian NET cancer research projects